THE NATIONAL HEALTH SERVICE ACT 2006

The Pharmaceutical Services (Advanced and Enhanced Services) (Amendments Relating to the COVID-19 and Adult Influenza Vaccination Service) (England) Directions 2026

The Secretary of State gives the following Directions in exercise of the powers conferred by sections 127, 128, 272(7) and (8) and 273(1) of the National Health Service Act 2006(**a**).

Citation, commencement, extent, application and interpretation

1.—(1) These Directions may be cited as the Pharmaceutical Services (Advanced and Enhanced Services) (Amendments Relating to the COVID-19 and Adult Influenza Vaccination Service) (England) Directions 2026.

(2) These Directions come into force immediately after they are signed.

(3) These Directions extend to England and Wales but apply in relation to England only.

(4) In these Directions, "the 2013 Directions" means the Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2013(**b**).

(**a**) 2006 c. 41. Section 127 has been amended by the Health and Social Care Act 2012 (c. 7) ("the 2012 Act"), Schedule 4, paragraph 64, and by the Health and Care Act 2022 (c. 31) ("the 2022 Act") Schedule 1, paragraph 1. Section 128 has been amended by the 2012 Act, Schedule 4, paragraph 65, and by the 2022 Act, Schedule 1, paragraph 1.

(**b**) Signed on 12th March 2013, and amended by: the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2013, signed on 16th September 2013; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2013, signed on 6th December 2013, which also revoked the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2013; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2014, signed on 12th March 2014; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2014, signed on 5th December 2014; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2015, signed on 15th September 2015; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2016, signed on 30th August 2016; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No.2) Directions 2016, signed on 30th November 2016; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2017, signed on 29th August 2017; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2018, signed on 8th March 2018; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2018, signed on 31st August 2018; and the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2019, signed on 13th March 2019; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2019, signed on 22nd August 2019; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 3) Directions 2019, signed on 11th September 2019, the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 4) Directions 2019, signed on 24th October 2019; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2020, signed on 6th March 2020; the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) Directions 2020, signed on 27th March 2020; and the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (Amendment) (England) Directions 2020, signed on 30th June 2020; the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (England) (Amendment) (No.2) Directions 2020, signed on 28th August 2020; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2021, signed on 9th March 2021; the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (England) (Amendment) Directions 2021, signed on 29th March 2021; the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (Amendment) (England) Directions 2021, signed on 29th June 2021; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2021, signed on 1st September 2021; the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (Further Amendments) (England) Directions 2021, signed on 30th September 2021; the Pharmaceutical Services (Smoking Cessation Service) (England) Directions 2022, signed on 9th March 2022; the Pharmaceutical Services (Advanced and Enhanced Services) (Further Amendment) Directions 2022, signed on 5th April 2022; the Pharmaceutical Services (Advanced and Enhanced Services) (Further Amendments) Directions 2022, signed on 24th August 2022; the

Amendment of direction 2 of the 2013 Directions

2.—(1) Direction 2 of the 2013 Directions (interpretation) is amended as follows.

(2) Omit the definitions of "CPSIVAS", "CPSIVAS service specification", "national PGD" and "national protocol."

(3) At the appropriate places in the alphabetical order insert—

""CPCAIVAS" means the Community Pharmacy COVID-19 and Adult Influenza Vaccination Advanced Service;";

""CPCAIVAS service specification" means the service specification for the community pharmacy COVID-19 and adult influenza vaccination advanced service entitled "Community Pharmacy Advanced Service Specification COVID-19 and Adult Influenza Vaccination programme: 1 April 2026 to 31 March 2027", or that service specification if it is revised by NHS England, as revised by NHS England from time to time(**a**);";

""point of care system" means a clinical IT system that has been assured by the commissioner to record COVID-19 vaccination events and adult influenza vaccination events;"; and

""year round pathway patient" means those patients who are eligible for a catch-up or an additional dose of COVID-19 vaccination in accordance with the Green Book(**b**);".

Amendment of directions 7A and 7B of the 2013 Directions

3. For directions 7A and 7B of the 2013 Directions (Community Pharmacy Seasonal Influenza Vaccination Advanced Service: general matters and preconditions to making arrangements and Community Pharmacy Seasonal Influenza Vaccination Advanced Service: ongoing conditions of arrangements)(**c**), substitute—

"Community Pharmacy COVID-19 and Adult Influenza Vaccination Advanced Service: general matters and preconditions to making arrangements

7A.—(1) NHS England must make arrangements for the provision of a service as part of the CPCAIVAS with any pharmacy contractor (P) who—

(a) meets the requirements set out in paragraphs (3) to (16);

(b) wishes to enter into such arrangements or is required to do so by virtue of regulation 66 of the Pharmaceutical Regulations (conditions relating to providing directed services); and

(c) has notified the commissioner of their intention to provide either COVID-19 and adult influenza vaccinations to patients or adult influenza vaccinations

---

Pharmaceutical Services (Advanced and Enhanced Services) (Amendment) (England) Directions 2023, signed on 28th March 2023; the Pharmaceutical Services (NHS Pharmacy Contraception Service and Other Amendments) (England) Directions 2023, signed on 17th April 2023; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Further Amendments) Directions 2023, signed on 29 August 2023; the Pharmaceutical Services (Advanced and Enhanced Services) (Further Amendments) (No. 2) (England) Directions 2023, signed on 3rd November 2023; the Pharmaceutical Services (Advanced and Enhanced Services) (Further Amendments) (No. 3) (England) Directions 2023, signed on 30th November 2023; the Pharmaceutical Services (Advanced and Enhanced Services) (Further Amendments) (No. 4) (England) Directions 2023, signed on 19th December 2023; the Pharmaceutical Services (Advanced and Enhanced Services) (Amendments Relating to Influenza Vaccination Service) (England) Directions 2024, signed on 29th August 2024; the Pharmaceutical Services (Advanced and Enhanced Services) (Amendments Relating to the Adult Influenza Vaccination Service) (England) Directions 2025, signed on 28th August 2025; and the Pharmaceutical Services (Advanced and Enhanced Services) (Further Amendments) (England) Directions 2025, signed on 24th October 2025.

(**a**) NHS publication approval reference: PRN02245_i.

(**b**) The up to date version is available at https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book.

(**c**) As substituted by the Pharmaceutical Services (Advanced and Enhanced Services) (Amendments Relating to the Adult Influenza Vaccination Service) (England) Directions 2025, signed on 28th August 2025.

to patients, by the relevant dates and in the manner as set out in the CPCAIVAS service specification.

(2) The aims of the CPCAIVAS are—

(a) to protect those who are most at risk of serious illness or death should they develop COVID-19 or influenza;

(b) to sustain and maximise the uptake and co-administration of COVID-19 and adult influenza vaccinations to patients by continuing to build the capacity of community pharmacies as an alternative to general practice attendance; and

(c) to provide more opportunities and improve convenience for eligible patients to access COVID-19 vaccinations and adult influenza vaccinations.

(3) P must be satisfactorily complying with P's obligations under Schedule 4 to the Pharmaceutical Services Regulations (terms of service of NHS pharmacies) in respect of the provision of essential services and an acceptable system of clinical governance.

(4) Any vaccinator who is to be involved in the administration of vaccines as part of the service must have the necessary experience, skills, competence and training to administer vaccines in line with the requirements of the CPCAIVAS service specification, and records of training must be kept in line with those requirements.

(5) Pharmacy staff who are not vaccinators but who might be asked to perform a role as part of the service must have been appropriately trained, including updates, in line with the requirements of the CPCAIVAS service specification.

(6) Any vaccinator who is to be providing COVID-19 vaccinations to patients aged under 18 years, or if COVID-19 or adult influenza vaccinations are to be undertaken at a patient's own home must have a valid enhanced Disclosure and Barring Service (DBS) certificate demonstrating that they have been checked against the adult and children's barred list.

(7) The responsible pharmacist at the pharmacy premises at or from which the service is to be provided, is to be professionally responsible for overseeing the CPCAIVAS, and if the responsible pharmacist is unable to provide sufficient oversight, (for example due to workload or where vaccinations are undertaken away from the pharmacy premises), an on-site pharmacist or pharmacy technician responsible for the delivery of the CPCAIVAS must be linked and work closely with the responsible pharmacist and the superintendent pharmacist through an appropriate governance framework to ensure appropriate oversight of the service.

(8) P must have in place, at the pharmacy premises or for any other locations from which the service is to be provided, appropriate standard operating procedures for the service (which may be available electronically), having regard to the CPCAIVAS service specification, about which pharmacy staff (if there is any role that they may be asked to perform as part of the service) have received appropriate training and which include procedures in respect of—

(a) cold chain integrity;

(b) the escalation of any issues identified (clinical and non-clinical);

(c) signposting details;

(d) record keeping and staff training.

(9) P must be able to provide the services which are part of the CPCAIVAS at an acceptable location, and for these purposes "acceptable location" means, where the service is being provided—

(a) at P's pharmacy premises—

(i) in a room for consultations which meets the applicable requirements of paragraph 28A of Schedule 4 to the Pharmaceutical Services Regulations(**a**) (premises requirements in respect of consultation rooms), or

(ii) at an alternative location where there are suitable facilities available (allowing for infection control standards to be maintained and patient confidentiality and dignity to be respected), but only to the extent this is permitted by the CPCAIVAS service specification;

(b) elsewhere other than P's pharmacy premises, including at a patient's home, a care home or a community venue, a location where there are suitable facilities available (allowing for infection control standards to be maintained and patient confidentiality and dignity to be respected), but only to the extent that—

(i) this is permitted by the CPCAIVAS service specification,

(ii) P has obtained consent from the commissioner if P wishes to carry out vaccinations at a location other than at P's pharmacy premises,

(iii) this location is in the same NHS England region as P's registered premises, and

(iv) the majority of vaccinations must still be delivered from P's registered premises, except for distance selling premises pharmacies.

(10) Distance selling premises pharmacies are not permitted to provide vaccinations to patients at the pharmacy premises.

(11) P must ensure that where vaccinations are undertaken away from the pharmacy premises, P has in place arrangements to ensure there is an on-site pharmacist or pharmacy technician responsible for the delivery of the CPCAIVAS off-site (or delivering the vaccination service themselves) and that—

(a) vaccines are administered by appropriately trained vaccinators in line with the appropriate legal mechanism;

(b) P has professional indemnity insurance that covers off-site vaccinations;

(c) vaccinators continue to adhere to all professional standards relating to vaccinations;

(d) vaccinators follow appropriate cold chain storage measures;

(e) the setting used to administer the vaccines is appropriate (including ensuring patient confidentiality and dignity can be respected); and

(f) staff appropriately dispose of any clinical waste or personal protective equipment used during the vaccination process.

(12) P is required to make arrangements for the removal and safe disposal of any clinical waste and personal protective equipment related to the provision of the CPCAIVAS (including where the vaccination is undertaken away from the pharmacy premises).

(13) Where P registers to provide COVID-19 vaccinations in addition to adult influenza vaccinations, access to COVID-19 vaccines is to be provided centrally by the commissioner and deliveries of the vaccine are to be made to P's registered premises, and vaccines must not be shared with other providers providing a similar

(**a**) Inserted by S.I. 2020/1126 and amended by S.I. 2023/1071.

vaccination service or moved (except as expressly permitted by the CPCAIVAS service specification) without the express prior consent of the commissioner.

(14) P must adhere to the requirements in the CPCAIVAS service specification in relation to the ordering of COVID-19 vaccine supply, maintaining and providing accurate capacity and clinic session data, stock and inventory data and record-keeping, which includes providing support in relation to stock forecasting, use and ordering of COVID-19 vaccine as requested by the commissioner.

(15) P must adhere to the requirements in the CPCAIVAS service specification in relation to the ordering of influenza vaccine supply, following guidance in the Flu Letter on recommended vaccines.

(16) Adult influenza clinics must be planned using the recommended licensed influenza vaccines as set out in the Flu Letter and the Green Book(**a**), (and where P does not have a recommended influenza vaccine in stock, patients should be directed to an alternative provider who has stock of a recommended vaccine or told to rebook when the stock is available), and administration of alternative vaccines must only be considered where the recommended vaccine is not available to order from any manufacturer or P's regular wholesaler, or on an exceptional basis where there is a valid reason why the patient may not return for a further appointment.

Community Pharmacy COVID-19 and Adult Influenza Vaccination Advanced Service: ongoing conditions of arrangements

7B.—(1) NHS England must ensure that arrangements pursuant to direction 7A(1) with a pharmacy contractor (P) include terms equivalent to the requirements set out in this direction.

(2) Only COVID-19 and influenza vaccines are to be administered as part of the service, and they must be administered in accordance with the requirements of the CPCAIVAS service specification and within the dates published by the commissioner.

(3) The only COVID-19 and influenza vaccines to be administered as part of the service are those permitted by or by virtue of the CPCAIVAS service specification.

(4) Vaccines must only be administered to patients who are eligible to receive vaccination (by their inclusion in a Joint Committee on Vaccination and Immunisation cohort(**b**) which has been announced and authorised by the commissioner as eligible for vaccination by community pharmacy), and P must comply with the announcements, authorisations and priority orders in place at the date of the administration of a vaccine, and throughout the term (which are subject to change).

(5) P must ensure that vaccinations offered under the CPCAIVAS are provided in line with the Green Book(**c**) (which outlines all relevant details on the dosage, timings and administration of COVID-19 and influenza vaccines, and disposal of clinical waste), and P must ensure that vaccines are offered in line with any Joint Committee on Vaccination and Immunisation guidance on the co-administration of vaccines or the required interval between any vaccinations, including where they have been administered by another provider.

(**a**) The up to date version is available at https://www.gov.uk/government/collections/immunisation-against-infectious-diseas e-the-green-book.

(**b**) The Joint Committee on Vaccination and Immunisation publishes its statement on patients who are eligible for the vaccines at: https://www.gov.uk/health-and-social-care/health-protection-immunisation.

(**c**) The up to date version is available at https://www.gov.uk/government/collections/immunisation-against-infectious-diseas e-the-green-book.

(6) P must have in place and keep under review at the pharmacy premises or any other locations from which the service is to be provided appropriate standard operating procedures for the service (which may be available electronically), as described in direction 7A(8), about which pharmacy staff (if there is any role that they may be asked to perform as part of the service) must have received appropriate training.

(7) P must ensure that the requirements in the CPCAIVAS service specification that apply to any responsible pharmacist and the superintendent pharmacist of P are adhered to, including through an appropriate governance framework.

(8) The responsible pharmacist at the registered pharmacy premises is to be professionally responsible for overseeing the CPCAIVAS, and if the responsible pharmacist is unable to provide sufficient oversight, (for example due to workload or where vaccinations are undertaken away from the pharmacy premises), an on-site pharmacist or pharmacy technician responsible for the delivery of the CPCAIVAS must be linked and work closely with the responsible pharmacist and superintendent pharmacist through an appropriate governance framework to ensure appropriate oversight of the service.

(9) Vaccines must only be administered by an appropriately trained vaccinator, and P must ensure that those involved in vaccination activity—

(a) have the necessary experience, skills, competence and training to administer vaccines in line with the requirements of the CPCAIVAS service specification, and records of training must be kept in line with those requirements;

(b) have the necessary experience, skills and training with regard to the recognition and initial management of anaphylaxis;

(c) are competent to deliver the service having regard to the applicable requirements of the CPCAIVAS service specification;

(d) understand and are authorised to work under the valid legal mechanism for administration of the vaccine in question;

(e) have read and understood the clinical guidance published in the Green Book and the associated information for healthcare practitioners, and have a process in place to check any updates to these documents and the relevant legal mechanisms;

(f) are appropriately trained and made aware of the risks associated with the handling and disposal of clinical waste and that correct procedures are in place and used to minimise those risks, including a needle stick injury procedure;

(g) have a valid enhanced DBS check demonstrating that they have been checked against the adult and children's barred list if vaccinations are to be undertaken in the patient's own home (including a care home) or if COVID-19 vaccines are to be administered to patients under the age of 18.

(10) In relation to vaccine supply, handling and storage, P must ensure that—

(a) the receipt, storage, transportation and preparation of all vaccines is in accordance with any relevant medicines legislation, manufacturer's, MHRA, UKHSA and NHSE's instructions, and all associated guidance in the Green Book, and is undertaken with appropriate cold chain management (including appropriate and timely action when temperature deviations occur), clinical oversight and in accordance with governance arrangements which are in place in line with the CPAIVAS service specification;

(b) robust and reliable stock management processes are in place to minimise vaccine wastage whilst ensuring sufficient vaccine is available to support the vaccination offer to patients, and to mitigate risks associated with handling multiple vaccine types; and

(c) the vaccine is only stored overnight at Care Quality Commission/General Pharmaceutical Council registered premises, in accordance with approved medicines management arrangements.

(11) P must actively try to minimise wastage and persistent wastage above 30% of COVID-19 vaccine allocated may result in reduced or paused supply of vaccine to P, pending review by the commissioner.

(12) P must provide support in relation to stock forecasting, use and ordering of COVID-19 vaccine as requested by the commissioner.

(13) P must only provide the service at an acceptable location, and for these purposes, "acceptable location" has the same meaning as in direction 7A(9).

(14) If the service is provided at P's pharmacy premises and the patient expresses a preference for a vaccination to take place in a consultation room, P must respect that preference.

(15) Where the service is provided elsewhere than at P's pharmacy premises, P must ensure that all P's vaccinators are covered by an insurance or indemnity arrangement that covers vaccinating at the premises where the service is provided, and P must also ensure that, on each occasion the service is provided elsewhere than at P's premises, what needs to be in place by virtue of direction 7A(11) is also adhered to.

(16) P must not refuse to provide the service to a patient in the event that they are not registered with a general practitioner in England or because they do not have an NHS number.

(17) P must ensure the service is accessible, appropriate and sensitive to the needs of all service users, and that no patient is excluded or experiences particular difficulty in accessing and effectively using this service due to a protected characteristic, as outlined in the Equality Act 2010, including age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, sex or sexual orientation.

(18) Prior to vaccinations, a registered healthcare professional trained in vaccination and familiar with the characteristics of the vaccine being administered must:

(a) assess the patient to be eligible in accordance with the CPCAIVAS service specification and the Green Book;

(b) assess that the administration of the vaccine is clinically appropriate, (which will include providing information that the patient may need to make a final decision on whether to proceed with the vaccination); and

(c) seek the informed consent of the patient to the administration of the vaccine.

(19) P must ensure that—

(a) the patient is provided with the patient information leaflet for the vaccine or be directed to a web-based version of the leaflet; and

(b) the patient is informed about how information relating to their vaccination will be recorded and shared, providing detail in relation to that in line with the CPCAIVAS service specification.

(20) Where P can administer COVID-19 vaccinations to patients aged under 18 years—

(a) the patient must have been assessed as competent to consent and does consent, or

(b) the patient is not assessed as competent to consent but does not object and consent is provided by somebody with parental responsibility.

(21) In relation to the COVID-19 vaccination, P must—

(a) offer co-administration of both vaccines where clinically appropriate to each patient P is able to vaccinate subject to availability and where P has registered to provide both COVID-19 and adult influenza vaccinations;

(b) identify patients eligible for COVID-19 vaccination and/or adult influenza vaccination who present at the pharmacy and encourage them to take up the vaccination offer; and

(c) where the pharmacy contractor is registered to provide COVID-19 vaccinations, administer vaccines to patients aged 18 years or over only if the provisions at 7A(6) and 7B(9)(g) have been complied with.

(22) P must adhere to the requirements in the CPCAIVAS service specification in relation to the ordering of COVID-19 vaccine supply, maintaining and providing accurate capacity and clinical session data, stock and inventory data and record-keeping.

(23) P must not administer vaccines to patients who are housebound, in a care home, under 18 years of age (who are eligible for a COVID-19 vaccine only), nor to year round pathway patients who require an additional dose during the seasonal COVID-19 vaccination campaign or outside the announced and authorised COVID-19 vaccination campaigns unless so requested by the commissioner (which P may choose whether to accept or refuse) or if P approaches the commissioner and obtains consent to vaccinate these patients.

(24) P must offer COVID-19 vaccinations to patients through the national booking service(**a**) (and may offer co-administered COVID-19 and adult influenza vaccinations through the national booking service), and must comply with the requirements and minimum publication standards for national booking as set out in the CPCAIVAS service specification.

(25) P must offer vaccinations through advertised walk-in clinics via the NHS pharmacy services finder.

(26) The COVID-19 vaccine must not be used to administer vaccinations to private patients.

(27) As regards each patient vaccinated as part of the service who is registered with a general practitioner, P must ensure that the patient's general practitioner is notified (where this is known) in accordance with the CPCAIVAS service specification, including in the manner provided for in the CPCAIVAS service specification.

(28) If—

(a) a patient presents with an adverse drug reaction following the initial vaccination; and

(**a**) Available at https://digital.nhs.uk/services/vaccinations-national-booking-service.

(b) a pharmacist who is P or who is employed or engaged by P believes the adverse reaction is of clinical significance such that the patient's registered general practice should be informed,

this information should be shared with the registered general practice as soon as possible and a report submitted to the Medicines and Healthcare products Regulatory Agency under the Yellow Card Scheme(**a**).

(29) P must report any patient safety incidents in line with the Clinical Governance Approved Particulars for pharmacies.

(30) P must follow the UKHSA: "Vaccine incident guidance"(**b**) and local NHS arrangements for responding to and reporting errors in vaccine storage, handling and administration.

(31) P must maintain appropriate electronic records of P's provision of the service, in accordance with the CPCAIVAS service specification, including—

(a) ensuring that any staff recording the administration of a vaccine have received relevant training to be able to update records appropriately and accurately;

(b) using an NHS assured point of care system in the manner required by, and for the purpose specified in, the CPCAIVAS service specification;

(c) having robust user and access management processes (with frequent updates to system access levels); and

(d) ensuring same day record keeping (unless where exceptional circumstances apply).

(32) P must comply with the arrangements for sharing data with NHS BSA and the service commissioners that are necessary for the performance of obligations under the CPCAIVAS service specification that are part of the management of the service, with any sharing of personal data being subject to an appropriate level of confidentiality.

(33) If P temporarily ceases to provide the services, P must update their listing via NHS Profile Manager and the national booking service as soon as practically possible to reflect that the service is not available from the pharmacy, and where P is providing COVID-19 vaccinations P must also opt out of replenishment for COVID-19 vaccine in the federated data platform(**c**).

(34) If P wishes to permanently cease providing the service, P must notify the commissioner giving 30 days' notice in accordance with the CPCAIVAS service specification including that P must continue to provide the service for the duration of the notice period, and update the national booking service and NHS Profile Manager when P ceases provision of the service, and the conditions relating to de-registration set out in the CPCAIVAS service specification are to apply.

(35) If P fails to comply with a requirement of the arrangements, as provided for in this direction and the CPCAIVAS service specification, NHS England may impose the sanctions for that failure that are provided for in the CPCAIVAS service specification (in addition to the other sanctions that may be imposed in accordance with the Pharmaceutical Regulations).".

(**a**) Available at https://yellowcard.mhra.gov.uk/.
(**b**) Available at https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors.
(**c**) Available at https://www.england.nhs.uk/digitaltechnology/nhs-federated-data-platform/.

Signed by authority of the Secretary of State for Health and Social Care

Peter Lilford
Deputy Director, Pharmacy, Eye Care and Controlled Drugs
Department of Health and Social Care

26 March 2026